ClinicalTrials.gg
CompletedNCT00108823Updated Oct 26, 2016

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

A Phase 3 interventional study of Roflumilast in Chronic Obstructive Pulmonary Disease, COPD, sponsored by AstraZeneca. Completed at 16 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-10-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 32
550 · median 154
Started
2004
with 1 other
Phase 3
16 of 32
none open now
Registered
3rd of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 2 that started in 2004, is one of 16 in phase 3, and was the 3rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease, COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Written
  • Patients with a history of for at least 12 months as defined by the GOLD (Global Initiative on Obstructive Lung Diseases) criteria (2003)
  • Age ≥ 40 years
  • /FVC ratio (post-bronchodilator) ≤ 70%
  • FEV1 (post-bronchodilator) ≤ 65% of predicted
  • FRC (post-bronchodilator) ≤ 120% of predicted
  • Clinically stable COPD within 4 weeks prior to baseline visit (B0).
  • Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit (B0) or a willingness to have a chest x-ray performed at visit (B0).

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic glucocorticosteroids not stopped at least 4 weeks prior to the baseline visit (B0)
  • Non smoker, current smoker or ex-smoker (smoking cessation at least one year ago) with a smoking history of \< 10 pack years
  • Suffering from any concomitant disease that might interfere with study procedures or evaluation
  • Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit (B0)
  • Diagnosis of asthma and/or other relevant lung disease (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], and active tuberculosis)
  • Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 2 months preceding the baseline visit (B0).
  • Known alpha-1-antitrypsin deficiency
  • Need for long term oxygen therapy defined as ≥ 15 hours/day
  • abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator)
  • Known infection with , active hepatitis and/or liver insufficiency
  • Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within 5 years prior to study start
  • Clinically significant cardiopulmonary abnormalities (diagnosed clinically or by x-ray/) that are not related to COPD and that require further evaluation
  • Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial
  • The female patient is of and is not using and is not willing to continue to use a medically reliable method of for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless she is surgically sterilized/hysterectomized or > 1 year or any other criteria considered sufficiently reliable by the investigator in individual cases
  • Participation in another study (use of product) within 30 days preceding the baseline visit (B0) or re-entry of patients already enrolled in this trial
  • Suspected inability or unwillingness to comply with study procedures
  • Alcohol or drug abuse
  • Inability to follow study procedures due to, for example, language problems or psychological disorders
  • Use of prohibited drugs
  • Suspected to the study medication and/or to any ingredients of the study medication (roflumilast) or rescue medication
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
550 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Lung function parameters indicative of hyperinflation in patients with COPD

Secondary outcomes

  1. Mean change from randomization to endpoint in additional pre and post bronchodilator spirometric and lung volume parameters

  2. Measurement of quality of life parameters and dyspnea

07

Study locations

16 sites
  • ALTANA Pharma
    Cities in California, California, United States
  • ALTANA Pharma
    Cities in Colorado, Colorado, United States
  • ALTANA Pharma
    Cities in Florida, Florida, United States
  • ALTANA Pharma
    Cities in Missouri, Missouri, United States
  • ALTANA Pharma
    Cities in New Mexico, New Mexico, United States
  • ALTANA Pharma
    Cities in New York, New York, United States
  • ALTANA Pharma
    Cities in Oregeon, Oregon, United States
  • ALTANA Pharma
    Cities in South Carolina, South Carolina, United States
  • ALTANA Pharma
    Cities in Texas, Texas, United States
  • ALTANA Pharma
    Cities in Washington, Washington, United States
  • ALTANA Pharma
    Cities in Canada, Canada
  • ALTANA Pharma
    Cities in France, France
  • ALTANA Pharma
    Cities in Poland, Poland
  • ALTANA Pharma
    Cities in South Africa, South Africa
  • ALTANA Pharma
    Cities in Spain, Spain
  • ALTANA Pharma
    Cities in the United Kingdom, United Kingdom
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00108823
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 20, 2005
Start date
Oct 2004
Last update
Oct 26, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion